Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2

Journal of Molecular Biology

Volumn 429, Issue 2, 2017, Pages 208-219

  Popovic, B ^a   Breed, J ^b   Rees, D G ^a   Gardener, M J ^a   Vinall, L M K ^a   Kemp, B ^a   Spooner, J ^a   Keen, J ^a   Minter, R ^a   Uddin, F ^a   Colice, G ^b   Wilkinson, T ^a   Vaughan, T ^a   May, R D ^a  

^a MEDIMMUNE LTD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

antibody structure; antibody antigen complex; crystal structure; mutagenesis; tralokinumab

Indexed keywords

ALANINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; LIGAND; TRALOKINUMAB; COMPLEMENTARITY DETERMINING REGION; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN BINDING;

ALPHA HELIX; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY REACTION; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BIOCHEMICAL ANALYSIS; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME MECHANISM; HUMAN; HYDROGEN BOND; LIGHT CHAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; IC50; METABOLISM; MOLECULAR CLONING; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ASTHMA; CLONING, MOLECULAR; COMPLEMENTARITY DETERMINING REGIONS; CRYSTALLOGRAPHY, X-RAY; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY;

EID: 85008658892     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2016.12.005     Document Type: Article

References (35)

1. [1] LaPorte, S.L., Juo, Z.S., Vaclavikova, J., Colf, L.A., Qi, X., Heller, N.M., Keegan, A.D., Garcia, K.C., Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132 (2008), 259–272, 10.1016/j.cell.2007.12.030.
2. [2] Lacy, E.R., Equilibrium and kinetic analysis of human interleukin-13 and IL-13 receptor alpha-2 complex formation. J. Mol. Recognit. 25 (2012), 184–191, 10.1002/jmr.2150.
3. [3] Chandriani, S., DePianto, D.J., N'Diaye, E.N., Abbas, A.R., Jackman, J., Bevers, J. III, Ramirez-Carrozzi, V., Pappu, R., Kauder, S.E., Toy, K., Ha, C., Modrusan, Z., Wu, L.C., Collard, H.R., Wolters, P.J., Egen, J.G., Arron, J.R., Endogenously expressed IL-13Ralpha2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J. Immunol. 193 (2014), 111–119, 10.4049/jimmunol.1301761.
4. [4] Zheng, T., Liu, W., Oh, S.Y., Zhu, Z., Hu, B., Homer, R.J., Cohn, L., Grusby, M.J., Elias, J.A., IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung. J. Immunol. 180 (2008), 522–529 (180/1/522 [pii]).
5. [5] Kasaian, M.T., Raible, D., Marquette, K., Cook, T.A., Zhou, S., Tan, X.Y., Tchistiakova, L., IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J. Immunol. 187 (2011), 561–569, 10.4049/jimmunol.1100467.
6. [6] Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R.K., Kitani, A., IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12 (2006), 99–106 (nm1332 [pii]).
7. [7] May, R.D., Fung, M., Strategies targeting the IL-4/IL-13 axes in disease. Cytokine 75 (2015), 89–116 (S1043-4666(15)00204-5 [pii]).
8. [8] Corren, J., Lemanske, R.F., Hanania, N.A., Korenblat, P.E., Parsey, M.V., Arron, J.R., Harris, J.M., Scheerens, H., Wu, L.C., Su, Z., Mosesova, S., Eisner, M.D., Bohen, S.P., Matthews, J.G., Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365 (2011), 1088–1098, 10.1056/NEJMoa1106469.
9. [9] Hanania, N.A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S.K., Cheu, M., Putnam, W.S., Murray, E., Scheerens, H., Holweg, C.T., Maciuca, R., Gray, S., Doyle, R., McClintock, D., Olsson, J., Matthews, J.G., Yen, K., Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70 (2015), 748–756, 10.1136/thoraxjnl-2014-206719.
10. [10] Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R.D., Geba, G.P., Molfino, N.A., A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur. Respir. J. 41 (2013), 330–338, 10.1183/09031936.00223411.
11. [11] Brightling, C.E., Chanez, P., Leigh, R., O'Byrne, P.M., Korn, S., She, D., May, R.D., Streicher, K., Ranade, K., Piper, E., Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3 (2015), 692–701, 10.1016/S2213-2600(15)00197-6.
12. [12] Boguniewicz, M., Leung, D.Y., Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol. Rev. 242 (2011), 233–246, 10.1111/j.1600-065X.2011.01027.x.
13. [13] Beck, L.A., Thaci, D., Hamilton, J.D., Graham, N.M., Bieber, T., Rocklin, R., Ming, J.E., Ren, H., Kao, R., Simpson, E., Ardeleanu, M., Weinstein, S.P., Pirozzi, G., Guttman-Yassky, E., Suarez-Farinas, M., Hager, M.D., Stahl, N., Yancopoulos, G.D., Radin, A.R., Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 371 (2014), 130–139, 10.1056/NEJMoa1314768.
14. [14] Thom, G., Cockroft, A.C., Buchanan, A.G., Candotti, C.J., Cohen, E.S., Lowne, D., Monk, P., Shorrock-Hart, C.P., Jermutus, L., Minter, R.R., Probing a protein–protein interaction by in vitro evolution. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 7619–7624 (0602341103 [pii]).
15. [15] May, R.D., Monk, P.D., Cohen, E.S., Manuel, D., Dempsey, F., Davis, N.H., Dodd, A.J., Corkill, D.J., Woods, J., Joberty-Candotti, C., Conroy, L.A., Koentgen, F., Martin, E.C., Wilson, R., Brennan, N., Powell, J., Anderson, I.K., Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br. J. Pharmacol. 166 (2012), 177–193, 10.1111/j.1476–5381.2011.01659.x.
16. [16] Teplyakov, A., Obmolova, G., Wu, S.J., Luo, J., Kang, J., O'Neil, K., Gilliland, G.L., Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607. J. Mol. Biol. 389 (2009), 115–123, 10.1016/j.jmb.2009.03.076.
17. [17] Ultsch, M., Bevers, J., Nakamura, G., Vandlen, R., Kelley, R.F., Wu, L.C., Eigenbrot, C., Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J. Mol. Biol. 425 (2013), 1330–1339, 10.1016/j.jmb.2013.01.024.
18. [18] Fransson, J., Teplyakov, A., Raghunathan, G., Chi, E., Cordier, W., Dinh, T., Feng, Y., Giles-Komar, J., Gilliland, G., Lollo, B., Malia, T.J., Nishioka, W., Obmolova, G., Zhao, S., Zhao, Y., Swanson, R.V., Almagro, J.C., Human framework adaptation of a mouse anti-human IL-13 antibody. J. Mol. Biol. 398 (2010), 214–231, 10.1016/j.jmb.2010.03.004.
19. [19] Moy, F.J., Diblasio, E., Wilhelm, J., Powers, R., Solution structure of human IL-13 and implication for receptor binding. J. Mol. Biol. 310 (2001), 219–230, 10.1006/jmbi.2001.4764.
20. [20] Lawrence, M.C., Colman, P.M., Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234 (1993), 946–950, 10.1006/jmbi.1993.1648.
21. [21] Li, Y., Li, H., Yang, F., Smith-Gill, S., Mariuzza, R.A., X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat. Struct. Mol. Biol. 10 (2003), 482–488.
22. [22] Kunik, V., Ofran, Y., The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops. Protein Eng. Des. Sel. 26 (2013), 599–609, 10.1093/protein/gzt027.
23. [23] Cui, L., Jia, J., Ma, C.F., Li, S.Y., Wang, Y.P., Guo, X.M., Li, Q., Yu, H.B., Liu, W.H., Gao, L.B., IL-13 polymorphisms contribute to the risk of asthma: a meta-analysis. Clin. Biochem. 45 (2012), 285–288, 10.1016/j.clinbiochem.2011.12.012.
24. [24] Heinzmann, A., Mao, X.Q., Akaiwa, M., Kreomer, R.T., Gao, P.S., Ohshima, K., Umeshita, R., Abe, Y., Braun, S., Yamashita, T., Roberts, M.H., Sugimoto, R., Arima, K., Arinobu, Y., Yu, B., Kruse, S., Enomoto, T., Dake, Y., Kawai, M., Shimazu, S., Sasaki, S., Adra, C.N., Kitaichi, M., Inoue, H., Yamauchi, K., Tomichi, N., Kurimoto, F., Hamasaki, N., Hopkin, J.M., Izuhara, K., Shirakawa, T., Deichmann, K.A., Genetic variants of IL-13 signalling and human asthma and atopy. Hum. Mol. Genet. 9 (2000), 549–559 (ddd052 [pii]).
25. [25] Vladich, F.D., Brazille, S.M., Stern, D., Peck, M.L., Ghittoni, R., Vercelli, D., IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J. Clin. Invest. 115 (2005), 747–754, 10.1172/JCI22818.
26. [26] Brightling, C.E., Nordenmark, L.H., Jain, M., Piper, E., She, D., Braddock, M., Colice, G., Tornling, G., Effect of anti-IL-13 treatment on airway dimensions in severe asthma. Am. J. Respir. Crit. Care Med. 194 (2016), 118–120, 10.1164/rccm.201511-2224LE.
27. [27] Persic, L., Roberts, A., Wilton, J., Cattaneo, A., Bradbury, A., Hoogenboom, H.R., An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 187 (1997), 9–18 (S0378-1119(96)00628-2 [pii]).
28. [28] Daramola, O., Stevenson, J., Dean, G., Hatton, D., Pettman, G., Holmes, W., Field, R., A high-yielding CHO transient system: coexpression of genes encoding EBNA-1 and GS enhances transient protein expression. Biotechnol. Prog. 30 (2014), 132–141, 10.1002/btpr.1809.
29. [29] Otwinowski, Z., Minor, W., Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol., 276, 1996, 307.
30. [30] Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., McNicholas, S.J., Murshudov, G.N., Pannu, N.S., Potterton, E.A., Powell, H.R., Read, R.J., Vagin, A., Wilson, K.S., Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67 (2011), 235–242, 10.1107/S0907444910045749.
31. [31] McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007), 658–674, 10.1107/S0021889807021206.
32. [32] Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., Features and development of coot. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 486–501, 10.1107/S0907444910007493.
33. [33] Murshudov, G.N., Vagin, A.A., Dodson, E.J., Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997), 240–255, 10.1107/S0907444996012255.
34. [34] Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., BUSTER Version 2.11.2. 2011, Global Phasing Ltd., Cambridge, UK.
35. [35] Groves, M.A., Amanuel, L., Campbell, J.I., Rees, D.G., Sridharan, S., Finch, D.K., Lowe, D.C., Vaughan, T.J., Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity. MAbs 6 (2014), 236–245, 10.4161/mabs.27261.